Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of subcutaneous formulation of ALXN1210 with ENHANZE drug-delivery technology

Next Previous
Trial Profile

A phase 1 study of subcutaneous formulation of ALXN1210 with ENHANZE drug-delivery technology

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Haemolytic uraemic syndrome; Immunological disorders; Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Sponsors Alexion Pharmaceuticals

Most Recent Events

  • 24 Jul 2019 Status changed from planning to completed according to an Alexion Pharmaceuticals media release.
  • 26 Jul 2018 According to an Alexion Pharmaceuticals media release, the company has filed a Clinical Trial Application in the EU for subcutaneous ALXN1210 co-administered with Halozymes ENHANZE drug-delivery technology, PH20, and plans to initiate this phase I study in the second half of 2018.Pending co-formulation data, this next-generation subcutaneous formulation will be called ALXN1810 and has the potential to further extend the dosing interval to once every two weeks or once per month.
  • 23 Feb 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top